Literature DB >> 27072700

Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

Daniel T Gewirth1.   

Abstract

BACKGROUND: The high sequence and structural homology among the hsp90 paralogs - Hsp90α, Hsp90β, Grp94, and Trap-1 - has made the development of paralog-specific inhibitors a challenging proposition.
OBJECTIVE: This review surveys the state of developments in structural analysis, compound screening, and structure-based design that have been brought to bear on this problem.
RESULTS: First generation compounds that selectively bind to Hsp90, Grp94, or Trap-1 have been identified.
CONCLUSION: With the proof of principle firmly established, the prospects for further progress are bright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27072700      PMCID: PMC4995118          DOI: 10.2174/1568026616666160413141154

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  75 in total

Review 1.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

Authors:  Komal Jhaveri; Tony Taldone; Shanu Modi; Gabriela Chiosis
Journal:  Biochim Biophys Acta       Date:  2011-10-29

2.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

Authors:  Kwai-Ming J Cheung; Thomas P Matthews; Karen James; Martin G Rowlands; Katherine J Boxall; Swee Y Sharp; Alison Maloney; S Mark Roe; Chrisostomos Prodromou; Laurence H Pearl; G Wynne Aherne; Edward McDonald; Paul Workman
Journal:  Bioorg Med Chem Lett       Date:  2005-07-15       Impact factor: 2.823

Review 3.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

4.  Modulation of Akt kinase activity by binding to Hsp90.

Authors:  S Sato; N Fujita; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

Authors:  Justin T Ernst; Michael Liu; Harmon Zuccola; Timothy Neubert; Kevin Beaumont; Amy Turnbull; Adam Kallel; Bryan Vought; Dean Stamos
Journal:  Bioorg Med Chem Lett       Date:  2013-11-23       Impact factor: 2.823

6.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.

Authors:  Robert M Immormino; Yanlong Kang; Gabriela Chiosis; Daniel T Gewirth
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

7.  Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions.

Authors:  Philippe Meyer; Chrisostomos Prodromou; Bin Hu; Cara Vaughan; S Mark Roe; Barry Panaretou; Peter W Piper; Laurence H Pearl
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

8.  Substrate binding drives large-scale conformational changes in the Hsp90 molecular chaperone.

Authors:  Timothy O Street; Laura A Lavery; David A Agard
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

9.  Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation.

Authors:  Karen L Soldano; Arif Jivan; Christopher V Nicchitta; Daniel T Gewirth
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

10.  Mechanism of dimer formation of the 90-kDa heat-shock protein.

Authors:  T Nemoto; Y Ohara-Nemoto; M Ota; T Takagi; K Yokoyama
Journal:  Eur J Biochem       Date:  1995-10-01
View more
  23 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

3.  Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma.

Authors:  Dustin J E Huard; Vincent M Crowley; Yuhong Du; Ricardo A Cordova; Zheying Sun; Moya O Tomlin; Chad A Dickey; John Koren; Laura Blair; Haian Fu; Brian S J Blagg; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2018-02-20       Impact factor: 5.100

4.  Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

Authors:  Nanette L S Que; Vincent M Crowley; Adam S Duerfeldt; Jinbo Zhao; Caitlin N Kent; Brian S J Blagg; Daniel T Gewirth
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

Review 5.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

6.  Structures of Hsp90α and Hsp90β bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity.

Authors:  John D Huck; Nanette L S Que; Sahil Sharma; Tony Taldone; Gabriela Chiosis; Daniel T Gewirth
Journal:  Proteins       Date:  2019-06-12

7.  Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors.

Authors:  David S Huang; Emmanuelle V LeBlanc; Tanvi Shekhar-Guturja; Nicole Robbins; Damian J Krysan; Juan Pizarro; Luke Whitesell; Leah E Cowen; Lauren E Brown
Journal:  J Med Chem       Date:  2019-09-26       Impact factor: 7.446

8.  Tritium-labeled agonists as tools for studying adenosine A2B receptors.

Authors:  Sonja Hinz; Wessam M Alnouri; Ulrich Pleiss; Christa E Müller
Journal:  Purinergic Signal       Date:  2018-05-11       Impact factor: 3.765

9.  5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.

Authors:  Shanshan Liu; Timothy O Street
Journal:  Protein Sci       Date:  2016-10-04       Impact factor: 6.725

10.  Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.

Authors:  Vincent M Crowley; Dustin J E Huard; Raquel L Lieberman; Brian S J Blagg
Journal:  Chemistry       Date:  2017-09-27       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.